Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans

Hypertension

Volumn 28, Issue 6, 1996, Pages 961-966

  Gandhi, Sanjay K ^a   Ryder, Diane H ^a   Brown, Nancy J ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

aldosterone; angiotensin II; losartan; receptors, angiotensin; renal circulation

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; 4 AMINOHIPPURIC ACID; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; LOSARTAN; RENIN; SODIUM CHLORIDE;

ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; HUMAN; HUMAN EXPERIMENT; KIDNEY; KIDNEY PLASMA FLOW; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL;

EID: 0029830450     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.28.6.961     Document Type: Article

References (41)

1. 1 receptors in renin transgenic rats. Circ Res. 1995;77:73-79.
2. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PB. Hypotensive action of DuP753, an angiotensin II antagonist, in spontaneously hypertensive rats: nonpeptide angiotensin II receptor antagonists: X. Hypertension. 1990; 15:459-468.
3. Wong PC, Price WA, Chiu AT, Carini DJ, Duncia JV, Johnson AL, Wexler RR, Timmermans PB. Nonpeptide angiotensin II receptor antagonists: studies with EXP9270and DuP753. Hypertension. 1990; 15:823-834.
4. Tofovic SP, Pong AS, Jackson EK. Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats. Hypertension. 1991;18:774-782.
5. MacFayden RJ, Tree M, Lever AF, Reid JL. Haemodynamic and hormonal responses to losartan (DuP753/MK954) infusion during cardiac catheterization in conscious salt-deplete dogs. Clin Sci. 1993; 85:157-163.
6. DeGraaf GL, Pals DT, Couch SJ, Lawson JA. Hormonal and cardiovascular effects of losartan (DuP753), an angiotensin receptor antagonist, in non-human primates. J Pharmacol Exp Ther. 1992;264:6-10.
7. Christen Y, Waeber B, Nussberger J, Lee RJ, Timmermans PB, Branner HR. Dose-response relationships following oral administration of DuP753 to normal humans. Am J Hypenens. 1991;4:350S-354S.
8. Grossman E, Pelig E, Carroll J, Shamiss A, Rosenthal T. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypenens. 1994;7:1041-1044.
9. Burnier M, Rutchmann B, Nussberger J, Versaggi J, Shahinfar S, Waeber B, Brunner HR. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993;22:339-347.
10. Ohtawa M, Takayama K, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol. 1993; 35:290-297.
11. Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo M, McWilliams EJ, Bjornsson TD. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension. 1993;21:704-713.
12. Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, Blum R, Herman T, Abraham PA, Halstenson CN, Lo M, Lu H, Spector R. Biochemical effects of losartan, a non-peptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension. 1995;25:37-46.
13. Munafo A, Christen Y, Nussberger J, Shum L, Borland M, Lee RJ, Waeber B, Biollaz J, Brunner HR. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther. 1992; 51:513-521.
14. Christen Y, Waeber B, Nussberger J, Porchet M, Borland RM, Lee RJ, Maggon K, Shum L, Timmermans PB, Brunner HR. Oral administration of DuP753, a specific angiotensin II receptor antagonist, to normal male volunteers. Circulation. 1991;83:1333-1342.
15. Gottleib SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKlock M. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88(part 1):1602-1609.
16. Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, Yoshinaga K. Hypotensive effect of losartan, a nonpeptide angiotensin n receptor antagonist, in essential hypertension. Am J Hypenens. 1993; 6:28-32.
17. Bauer IH, Reams GP, Wu Z, Lau-Sieckman A. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension. J Hum Hypenens. 1995;9:237-243.
18. Ogihara T, Arakawa K, Iimura O, Abe K, Saruta T, Ishii M, Hiwada K, Fujishima M, Fukiyama K. Open clinical studies on a new angiotensin II receptor antagonist, TCV 116. J Hypenens. 1994;12: S35-S38.
19. Smith MC, Barrows S, Meibohm A, Shahinfar S, Simpson RL, Wegel K, Dunn MJ. The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension. Am J Hypertens. 1995;8:1177-1183.
20. 1 receptor antagonist irbesartan in hypertension. Hypertension. 1995;25:22-29.
21. Aguilera G, Menard RH, Catt KJ. Regulatory actions of angiotensin II on receptors and steroidogenic enzymes in adrenal glomerulosa cells. Endocrinology. 1980;107:1277-1284.
22. Swartz SL, Williams GH, Hollenberg NK, Dluhy RG, Moore TJ. Primacy of the renin-angiotensin system in mediating the aldosterone response to sodium restriction. J Clin Endocrinol Metab. 1980;50: 1071-1074.
23. Hollenberg NK, Chenitz WR, Adams DF, Williams GH. Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man. J Clin Invest. 1974; 54:34-42.
24. Oelkers W, Brown JJ, Fraser R, Lever AF, Morton JJ, Robertson JI. Sensitization of the adrenal cortex to angiotensin II in sodium-deplete man. Circ Res. 1974;34:69-77.
25. Williams GH, Dluhy RG, Lifton RP, Moore TJ, Gleason R, Williams R, Hunt SC, Hopkins PN, Hollenberg NK. Non-modulation as an essential intermediate phenotype in essential hypertension. Hypertension. 1992;20:788-796.
26. Williams GH, Hollenberg NK. Functional derangements in the regulation of aldosterone secretion in hypertension. Hypertension. 1991; 18(suppl III):III-143-III-149.
27. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, Hollenberg NK. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest. 1983;72: 2115-2124.
28. Shoback DM, Williams GH, Hollenberg NK, Davies RO, Moore TJ, Dluhy RG. Endogenous angiotensin II as a determinant of sodium-modulated changes in tissue responsiveness to angiotensin II in normal man. J Clin Endocrinol Metab. 1983;57:764-770.
29. Taylor T, Moore TJ, Hollenberg NK, Williams GH. Converting-enzyme inhibition corrects the altered adrenal response to angiotensin II in essential hypertension. Hypertension. 1984;6:92-99.
30. Tuck ML, Dluhy RG, Williams GR. Sequential responses of the renin-angiotensin-aldosterone axis to acute postural change: effect of dietary sodium. J Lab Clin Med. 1975;86:754-763.
31. Workman RJ, Sussman CR, Burkett DW, Liddle GW. Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects. J Lab Clin Med. 1979;93:847-856.
32. Kubasik NP, Warren K, Sine HE. Evaluation of a new commercial radioimmunoassay kit for aldosterone using an iodinated tracer. Clin Biochem. 1979;10:59-61.
33. Schnurr E, Lahme W, Kuppers H. Measurement of renal clearance of inulin and PAH in the steady state without urine collection. Clin Nephrol. 1980;13:26-29.
34. Brun C. A rapid method for the determination of para-aminohippuric acid in kidney function test. J Lab Clin Med. 1951;37:955-958.
35. van Paassen P, de Zeeuw D, de Jong PE. Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension. J Cardiovasc Pharmacol. 1995;26:39-45.
36. Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, Waeber B, Brunner HR. Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension. 1995;25(part 1):22-29.
37. Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York. NY: Raven Press Publishers; 1990:1287-1317.
38. Kisch ES, Dluhy RG, Williams GH. Enhanced aldosterone response to angiotensin II in human hypertension. Circ Res. 1976;38:502-505.
39. Braunwald E. Pathophysiology of heart failure. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, Pa: WB Saunders Co; 1992:393-418.
40. Du Y, Yao A, Guo D, Inagami T, Wang DH. Differential regulation of angiotensin II receptor subtypes in rat kidney by low dietary sodium. Hypertension. 1995;25(part 2):872-877.
41. Healy HP, Ye M, Troyanoskaya M. Localization of angiotensin II type 1 receptor subtype mRNA in rat kidney. Am J Physiol. 1995; 268:F220-F226.